Telomir Pharmaceuticals (TELO) Receivables - Other (2023 - 2026)

Telomir Pharmaceuticals (TELO) posted Receivables - Other of $318234.0 for Q4 2025, up 144.8% sequentially from $130000.0 in Q3 2024.

Telomir Pharmaceuticals (TELO) Receivables - Other (2023 - 2026) Analysis & Trends

Telomir Pharmaceuticals has reported Receivables - Other for 3 years, with the latest figure at $318234.0 in Q4 2025.

Quarterly Receivables - Other changed N/A year-over-year to $318234.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $318234.0 (changed N/A YoY) and the FY2025 annual result came in at $318234.0, changed N/A from the prior year.
Receivables - Other climbed to $318234.0 in Q4 2025 per TELO's latest filing, from $130000.0 in the prior quarter.
Over five years, Receivables - Other peaked at $318234.0 in Q4 2025 and troughed at $130000.0 in Q4 2023.
A 3-year average of $167646.8 and a median of $130000.0 in 2023 frame the typical range for Receivables - Other.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn
10	Telomir Pharmaceuticals	68.14 Mn	68.14 Mn	-

Download Data